These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 22581753

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
    Zhang D, Zhang X, Ai J, Zhai Y, Liang Z, Wang Y, Chen Y, Li C, Zhao F, Jiang H, Geng M, Luo C, Liu H.
    Bioorg Med Chem; 2013 Nov 01; 21(21):6804-20. PubMed ID: 23993328
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
    Wang Y, Ai J, Wang Y, Chen Y, Wang L, Liu G, Geng M, Zhang A.
    J Med Chem; 2011 Apr 14; 54(7):2127-42. PubMed ID: 21405128
    [Abstract] [Full Text] [Related]

  • 4. N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.
    Saavedra O, Claridge S, Zhan L, Raeppel F, Granger MC, Raeppel S, Mannion M, Gaudette F, Zhou N, Isakovic L, Bernstein N, Déziel R, Nguyen H, Beaulieu N, Beaulieu C, Dupont I, Wang J, Macleod AR, Besterman JM, Vaisburg A.
    Bioorg Med Chem Lett; 2009 Dec 15; 19(24):6836-9. PubMed ID: 19896842
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 1.
    Kaieda A, Takahashi M, Fukuda H, Okamoto R, Morimoto S, Gotoh M, Miyazaki T, Hori Y, Unno S, Kawamoto T, Tanaka T, Itono S, Takagi T, Sugimoto H, Okada K, Snell G, Bertsch R, Nguyen J, Sang BC, Miwatashi S.
    ChemMedChem; 2019 May 17; 14(10):1022-1030. PubMed ID: 30945818
    [Abstract] [Full Text] [Related]

  • 7. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
    Williams DK, Chen XT, Tarby C, Kaltenbach R, Cai ZW, Tokarski JS, An Y, Sack JS, Wautlet B, Gullo-Brown J, Henley BJ, Jeyaseelan R, Kellar K, Manne V, Trainor GL, Lombardo LJ, Fargnoli J, Borzilleri RM.
    Bioorg Med Chem Lett; 2010 May 01; 20(9):2998-3002. PubMed ID: 20382527
    [Abstract] [Full Text] [Related]

  • 8. Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.
    An XD, Liu H, Xu ZL, Jin Y, Peng X, Yao YM, Geng M, Long YQ.
    Bioorg Med Chem Lett; 2015 Feb 01; 25(3):708-16. PubMed ID: 25529740
    [Abstract] [Full Text] [Related]

  • 9. Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.
    Bode CM, Boezio AA, Albrecht BK, Bellon SF, Berry L, Broome MA, Choquette D, Dussault I, Lewis RT, Lin MH, Rex K, Whittington DA, Yang Y, Harmange JC.
    Bioorg Med Chem Lett; 2012 Jun 15; 22(12):4089-93. PubMed ID: 22595176
    [Abstract] [Full Text] [Related]

  • 10. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
    Claridge S, Raeppel F, Granger MC, Bernstein N, Saavedra O, Zhan L, Llewellyn D, Wahhab A, Deziel R, Rahil J, Beaulieu N, Nguyen H, Dupont I, Barsalou A, Beaulieu C, Chute I, Gravel S, Robert MF, Lefebvre S, Dubay M, Pascal R, Gillespie J, Jin Z, Wang J, Besterman JM, MacLeod AR, Vaisburg A.
    Bioorg Med Chem Lett; 2008 May 01; 18(9):2793-8. PubMed ID: 18434145
    [Abstract] [Full Text] [Related]

  • 11. Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold.
    Zhao A, Gao X, Wang Y, Ai J, Wang Y, Chen Y, Geng M, Zhang A.
    Bioorg Med Chem; 2011 Jul 01; 19(13):3906-18. PubMed ID: 21665484
    [Abstract] [Full Text] [Related]

  • 12. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y, Onozaki Y, Sugimoto T, Kurihara H, Kamijo K, Kadowaki C, Tsujino T, Watanabe A, Otsuki S, Mitsuya M, Iida M, Haze K, Machida T, Nakatsuru Y, Komatani H, Kotani H, Iwasawa Y.
    Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4673-8. PubMed ID: 19589677
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.
    Zhang D, Ai J, Liang Z, Zhu W, Peng X, Chen X, Ji Y, Jiang H, Luo C, Geng M, Liu H.
    Bioorg Med Chem Lett; 2013 Apr 15; 23(8):2408-13. PubMed ID: 23474386
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X, Bao G, Wang L, Cheng M, Zhao M, Zhao S, Zhou H, Gong P.
    Bioorg Med Chem; 2016 Mar 15; 24(6):1331-45. PubMed ID: 26897090
    [Abstract] [Full Text] [Related]

  • 18. Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
    Yang Y, Zhang Y, Yang L, Zhao L, Si L, Zhang H, Liu Q, Zhou J.
    Bioorg Chem; 2017 Feb 15; 70():126-132. PubMed ID: 28043720
    [Abstract] [Full Text] [Related]

  • 19. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
    Li S, Zhao Y, Wang K, Gao Y, Han J, Cui B, Gong P.
    Bioorg Med Chem; 2013 Jun 01; 21(11):2843-55. PubMed ID: 23628470
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.